All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43910355" target="_blank" >RIV/00216208:11120/15:43910355 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064173:_____/15:#0000474

  • Result on the web

    <a href="http://dx.doi.org/10.1159/000381657" target="_blank" >http://dx.doi.org/10.1159/000381657</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1159/000381657" target="_blank" >10.1159/000381657</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

  • Original language description

    Romiplostim is recommended for the second- and third-line treatment of primary immune thrombocytopenia (ITP). We conducted a large, single-arm study (clinicaltrials.gov; NCT00508820) with broad entry criteria to evaluate the safety of romiplostim in adult ITP. Patients (n = 407) with ITP lasting 0.03-57.14 years and low platelet counts (median 14.0 x 10(9)/l) or uncontrolled bleeding received romiplostim for up to 4 years. The rates of treatment-related, serious adverse events, serious hemorrhage events, thromboembolic events and fatal events were similar to those reported in previous romiplostim trials (0.2, 0.4, 0.2 and 0.1/100 patient-weeks, respectively). Bone marrow reticulin was observed in 4 patients, but biopsies were not routinely performed sothe true incidence of this event cannot be determined. Type I collagen (nonserious, unrelated) was reported in 1 patient who likely had myelodysplastic syndrome. No new class of adverse events was reported. Platelet responses were achiev

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Acta Haematologica

  • ISSN

    0001-5792

  • e-ISSN

  • Volume of the periodical

    134

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    14

  • Pages from-to

    215-228

  • UT code for WoS article

    000362731500003

  • EID of the result in the Scopus database